4-(5 H -2,3-(2,5-Dimethyl-2,5-hexano)-5-methyl-8-nitrodibenzo[b,e][1,4]diazepin-11-yl)
benzoic acid (
HX531) is a novel
retinoid X receptor antagonist. This study provides evidence that
HX531 improves
leptin resistance without increasing plasma
leptin levels in KK-A y mice, an animal model with high plasma
leptin levels and
leptin resistance. Under normal dietary conditions, 3 weeks of treatment with
HX531 (0.03% and 0.06% food admixture) in KK-A y mice decreased plasma
leptin levels in a dose- and time-dependent manner, in addition to decreasing
body weight and mesenteric fatty tissue weight. To evaluate the effect of
HX531 on
leptin resistance,
leptin was injected intraperitoneally in the KK-A y mice for 4 days after 1 week of treatment with
HX531 (0.06% food admixture). This pretreatment with
HX531 resulted in exogenously administered
leptin causing a significant decrease in food intake. These results suggested that
HX531 decreased plasma
leptin levels accompanied by a decrease in fatty tissue content in the KK-A y mice and a simultaneous improvement in
leptin resistance. This is the first report that
HX531 improves
leptin resistance without increasing plasma
leptin level in KK-A y mice, under normal dietary conditions.